<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325986</url>
  </required_header>
  <id_info>
    <org_study_id>GD-B2014157</org_study_id>
    <nct_id>NCT02325986</nct_id>
  </id_info>
  <brief_title>Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer</brief_title>
  <official_title>Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and toxicity of radiotherapy
      concurrently with weekly chemotherapy of 5-FU and cisplatin in patients with postoperative
      locoregional recurrence of esophageal squamous cell carcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most optimal management for postoperative locoregional recurrence of oesophageal squamous
      cell carcinoma is still controversial. Several studies have reported the feasibility and
      efficacy of concurrent chemoradiotherapy (CCRT), mostly with three-weekly or four-weekly
      schedule of chemotherapy. However, treatment compliance was not quite satisfactory, probably
      due to treatment-related toxicities. Since CCRT with weekly chemotherapy regimens have
      demonstrated a favorable toxicity profile as well as promising survival in certain types of
      cancer, the investigators aimed to evaluate the efficacy and toxicity of radiotherapy
      concurrently with weekly chemotherapy with 5-fluorouracil (5-FU) and cisplatin for patients
      with postoperative locoregional recurrence of oesophageal squamous cell carcinoma in the
      investigators center.The prescribed dose of radiotherapy is generally 60Gy/28fr to tumor and
      50Gy/28fr to the clinical target volume.The concomitant chemotherapy is cisplatin 25mg/m2 on
      day 1, 5-FU 1176mg/m2 on day 1-3, repeated weekly for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>within 8 weeks after the treatment(plus or minus 5 days)</time_frame>
    <description>RECIST (Response Evaluation Criteria in Solid Tumors) was used to determine the tumor response. Tumor response was evaluated by CT 8 weeks after chemoradiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety: Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v3.0).</measure>
    <time_frame>up to 3 years</time_frame>
    <description>A 3 years follow-up from the enrollment or to the date of death from any cause or date of lost follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to 3 years</time_frame>
    <description>A 3 years follow-up from the enrollment or to the date of death from any cause or date of lost follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Weekly PF with radiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 cycles of weekly cisplatin and fluorouracil (cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3, repeated weekly for 4 weeks) concurrently with Intensity-modulated radiation therapy (60Gy/28fr).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)</description>
    <arm_group_label>Weekly PF with radiation</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)</description>
    <arm_group_label>Weekly PF with radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-modulated radiation therapy</intervention_name>
    <description>cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)</description>
    <arm_group_label>Weekly PF with radiation</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. R0 resection for primary esophageal squamous cell carcinoma with two-incision
             esophagectomy (Ivor Lewis approach)25 or three-incision (right thoracotomy, midline
             laparotomy and left cervical incisions) esophagectomy with cervical esophagogastric
             anastomosis.

          2. Absence of previous thoracic radiotherapy.

          3. Cervical and/or thoracic postoperative recurrence (biopsy proven or positron emission
             tomography/computed tomography (PET/CT) proven or follow-up computed tomography (CT)
             showed progression of disease).

          4. Absence of distant metastasis at recurrence.

          5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2

        Exclusion Criteria:

          1. Younger than 18 or older than 70 years of age.

          2. Eastern Cooperative Oncology Group (ECOG) performance status of 3 or above

          3. Other cancer history.

          4. Serious cardiac, liver, or pulmonary disease.

          5. Previous radiotherapy history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yujia Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P.R. China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujia Zhu, MD</last_name>
    <phone>86-20-87343385</phone>
    <email>zhuyuj@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>SYSU Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujia Zhu, Phd.</last_name>
      <phone>18520121368</phone>
      <email>sysucc@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Rice TW, Rusch VW, Apperson-Hansen C, Allen MS, Chen LQ, Hunter JG, Kesler KA, Law S, Lerut TE, Reed CE, Salo JA, Scott WJ, Swisher SG, Watson TJ, Blackstone EH. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22(1):1-8. doi: 10.1111/j.1442-2050.2008.00901.x.</citation>
    <PMID>19196264</PMID>
  </reference>
  <reference>
    <citation>Kato H, Miyazaki T, Nakajima M, Sohda M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K, Kuwano H. Prediction of hematogenous recurrence in patients with esophageal carcinoma. Jpn J Thorac Cardiovasc Surg. 2003 Nov;51(11):599-608.</citation>
    <PMID>14650590</PMID>
  </reference>
  <reference>
    <citation>Nakamura T, Ota M, Narumiya K, Sato T, Ohki T, Yamamoto M, Mitsuhashi N. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008 Sep;15(9):2451-7. doi: 10.1245/s10434-008-0016-x. Epub 2008 Jul 1.</citation>
    <PMID>18592318</PMID>
  </reference>
  <reference>
    <citation>Shioyama Y, Nakamura K, Ohga S, Nomoto S, Sasaki T, Yamaguchi T, Toba T, Yoshitake T, Terashima H, Honda H. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Jpn J Clin Oncol. 2007 Dec;37(12):918-23. doi: 10.1093/jjco/hym138.</citation>
    <PMID>18211982</PMID>
  </reference>
  <reference>
    <citation>Kobayashi R, Yamashita H, Okuma K, Shiraishi K, Ohtomo K, Nakagawa K. Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer. Dis Esophagus. 2014 Jan;27(1):72-8. doi: 10.1111/dote.12068. Epub 2013 Apr 2.</citation>
    <PMID>23551708</PMID>
  </reference>
  <results_reference>
    <citation>Yuan G, Wu L, Huang M, Li N, An J. A phase II study of concurrent chemo-radiotherapy with weekly nedaplatin in advanced squamous cell carcinoma of the uterine cervix. Radiat Oncol. 2014 Feb 18;9:55. doi: 10.1186/1748-717X-9-55.</citation>
    <PMID>24533532</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004 Feb;198(2):205-11.</citation>
    <PMID>14759776</PMID>
  </results_reference>
  <results_reference>
    <citation>Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005 Apr 1;23(10):2310-7. Erratum in: J Clin Oncol. 2006 Jan 20;24(3):531.</citation>
    <PMID>15800321</PMID>
  </results_reference>
  <results_reference>
    <citation>Bao Y, Liu S, Zhou Q, Cai P, Anfossi S, Li Q, Hu Y, Liu M, Fu J, Rong T, Li Q, Liu H. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol. 2013 Oct 18;8:241. doi: 10.1186/1748-717X-8-241.</citation>
    <PMID>24139225</PMID>
  </results_reference>
  <results_reference>
    <citation>Jingu K, Nemoto K, Matsushita H, Takahashi C, Ogawa Y, Sugawara T, Nakata E, Takai Y, Yamada S. Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-fluorouracil for postoperative locoregional recurrent esophageal cancer. BMC Cancer. 2006 Mar 4;6:50.</citation>
    <PMID>16515704</PMID>
  </results_reference>
  <results_reference>
    <citation>Ma DY, Tan BX, Liu M, Li XF, Zhou YQ, Lu Y. Concurrent three-dimensional conformal radiotherapy and chemotherapy for postoperative recurrence of mediastinal lymph node metastases in patients with esophageal squamous cell carcinoma: a phase 2 single-institution study. Radiat Oncol. 2014 Jan 19;9:28. doi: 10.1186/1748-717X-9-28.</citation>
    <PMID>24438695</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <last_update_submitted>November 19, 2015</last_update_submitted>
  <last_update_submitted_qc>November 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhu Yujia</investigator_full_name>
    <investigator_title>Attending physicion</investigator_title>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>esophageal carcinoma</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

